TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01632046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactate and bicarbonate buffered dialysis solutions
Description: Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactate and bicarbonate buffered dialysis solutions
Description: Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
Study: NCT05979285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N1-Headache App (by Curelator)
Description: Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
Study: NCT04574323

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Curative radiotherapy
Description: Standard curative radiotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Curative radiotherapy
Description: Standard curative radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic lifestyle intervention
Description: This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
Study: NCT04267003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study: NCT04268264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Description: twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
Study: NCT05064904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: never received RAAS blockers or received RAAS blockers before AKI.
Description: Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: never received RAAS blockers or received RAAS blockers before AKI.
Description: Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.
Study: NCT03078907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching film coated tablets
Study: NCT02059811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Diet
Description: The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
Study: NCT02828566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN ketamine
Description: Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
Study: NCT00891462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
Study: NCT01757262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg Ticagrelor
Description: Morning and Evening dose for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75mg Clopidogrel
Description: Morning dose for 5 days
Study: NCT01645904

Intervention type: BEHAVIORAL
Intervention: Audiotaped Focus Group
Description: Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.

Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.

Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
Study: NCT02828566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketamine
Description: Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN saline 0.9%
Description: Intranasal 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV saline 0.9%
Description: Intravenous 0.9% normal saline
Study: NCT01645904

Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.

Intervention type: BEHAVIORAL
Intervention: Audiotaped Interview
Description: Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website.

Intervention type: BEHAVIORAL
Intervention: Audiotaped Interview
Description: Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website.

Intervention type: BEHAVIORAL
Intervention: WAMMI Inventory
Description: Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: WAMMI Inventory
Description: Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
Study: NCT01964131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 20 mg
Description: Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: D961H HPMC capsule 20 mg
Description: Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
Study: NCT02373878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telecoaching plus Plate
Description: A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects were provided with institutional pamphlets on healthy eating and exercise habits
Study: NCT01695148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-Carotene Biofortified Maize Flour

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White Maize Flour
Study: NCT01908920

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment

Intervention type: OTHER
Group type: OTHER
Intervention: SHAM

Intervention type: OTHER
Group type: OTHER
Intervention: CONTROL
Study: NCT04268264

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional haemodialysis
Description: three times weekly 4-hour long haemodialysis sessions from the start
Study: NCT03392337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrowband UVB phototherapy
Description: Ultraviolet B phototherapy
Study: NCT02744508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron with dexamethasone
Study: NCT04136236

Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endoscopist
Description: Suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI. After a washout period, nonexpert endoscopists take the second assessment with AI assistance.
Study: NCT03166878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART019
Description: Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
Study: NCT04824131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cabotegravir (CAB)
Description: 30 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Description: 300 mg/200 mg fixed-dose combination tablets
Study: NCT03444779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial Tuberoplasty
Description: Kyphoplasty ballon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open technique
Description: Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
Study: NCT03686384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVT-15652
Description: 1 vial twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 vial twice daily
Study: NCT03461042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily before bedtime for 12 weeks since informed consent
Study: NCT06674200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenteric Molding Suturing Group
Description: During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regular
Description: The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues.
Study: NCT02919098

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bystander, a game-based bystander intervention program
Description: A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander, a game-based bystander intervention program
Description: A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Infection City, a game-based program about meningitis
Description: A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
Study: NCT04603053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: Participants will receive access to CBot-A app for 12 weeks.
Study: NCT02739165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by intravenous drip infusion in addition to standard of care steroid therapy
Study: NCT02946320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predilatation with non-compliant balloon
Description: Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilatation with scoring balloon (Scoroflex)
Description: Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilatation with cutting balloon (Flextome)
Description: Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
Study: NCT02922595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation through ILMA®
Description: It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation through ILTS®
Description: It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed
Study: NCT00604305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof
Description: Monofocal IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuity's AIOL
Description: Accommodating IOL
Study: NCT04357366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
Study: NCT04295473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced port laparoscopic gastrectomy
Description: The ports were reduced in the surgery of intervention arm.
Study: NCT03851380

Intervention type: BEHAVIORAL
Intervention: Psychological / Functional Assessment
Description: Psychological and functional assessment battery to characterize participants.

Intervention type: BEHAVIORAL
Intervention: Psychological / Functional Assessment
Description: Psychological and functional assessment battery to characterize participants.

Intervention type: OTHER
Intervention: Structural and Functional MRI
Description: Structural and functional magnetic resonance imaging session.

Intervention type: OTHER
Intervention: Structural and Functional MRI
Description: Structural and functional magnetic resonance imaging session.

Intervention type: DEVICE
Intervention: Transcranial Magnetic Brain Stimulation and MR Image Guidance
Description: MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.

Intervention type: DEVICE
Intervention: Transcranial Electrical Stimulation (tES)
Description: Home-based Transcranial Direct Current Stimulation
Study: NCT01850563

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
Study: NCT00664469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg/day over a 6-week course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Simvastatin 20, 40 and 80 mg
Description: Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Atorvastatin
Description: Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rosuvastatin
Description: Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study: NCT00648843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-release Tablets 5 mg
Description: 4x5mg, single dose fed
Study: NCT04007211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT13107
Description: Dose: 3mL, maximum 10mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalobarrier
Description: Dose: 10mL
Study: NCT01795638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Study: NCT00648843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 5 mg
Description: 4x5mg, single dose fed
Study: NCT04297670

Intervention type: OTHER
Intervention: Measurement of HPV types prevalence
Description: Self collected genital samples to be tested for the presence of different HPV types.
Study: NCT01795638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
Study: NCT01889550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to the website www.graviditetsportalen.dk
Description: The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Access to the website www.ouh.dk
Description: Access to the usual information from the hospital website
Study: NCT06459960

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Heated pool (32°C); Convention rehabilitation + Hydrotherapy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Convention
Description: Convention rehabilitation only
Study: NCT03547830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor for Conditioning before HSCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gcsf
Description: GCSF for Conditioning before HSCT.